Julius Baer Inflows Beat as CEO Bollinger Revamps Swiss Firm
Clients added a net 7.9 billion Swiss francs ($9.9 billion) in the six months through June, exceeding the 6.5 billion francs estimated by analysts. Net income fell 35% to 295 million francs, reflecting the impact of a previously disclosed loan loss allowance and a divestment in Brazil.
'We have good momentum and we are moving in the right direction,' Bollinger said in an interview.
The CEO and Chairman Noel Quinn are seeking to put the bank on a path for growth again after losses linked to the collapse of Rene Benko's real estate empire prompted the wealth manager to shake up its management. Yet a drip feed of bad news has complicated their mission.
In May, the bank booked another large loss from property developments it helped finance, resulting in a 130 million-franc charge related to its private debt business and selected positions in its mortgage operation.
Julius Baer said it hasn't found a need so far for more loan loss allowances as it continues the review of its credit book, which is expected to be completed 'in the next few months.'
Shares of Julius Baer rose 2.3% at 9:O2 a.m. in Zurich, paring losses this year to around 1%.
'While it is early days in the execution of the strategy, net new money trends and operating performance especially on costs were encouraging,' Anke Reingen, an analyst at RBC Capital Markets, wrote in a note.
As part of his turnaround plan, the new CEO has slashed the top management ranks and announced hundreds of job cuts. He has cautioned that his restructuring efforts will push up expenses at first, before bearing fruit from next year.
Julius Baer said on Tuesday that 78 relationship managers have left so far this year, most of them for performance reasons.
(Updates with CEO comment in third paragraph, shares in seventh.)
More stories like this are available on bloomberg.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
21 minutes ago
- Mint
Alaska Air Brings Back Annual Profit Outlook on Improved Demand
(Bloomberg) -- Alaska Air Group Inc. provided a new profit outlook for the year following an upturn in demand from business travelers who set aside trips early in the year on concerns over possible tariffs and worsening inflation. Average fares and revenue have improved in recent bookings at both Alaska and its Hawaiian Airlines unit, leading to a 2025 adjusted profit outlook of more than $3.25 a share, the carrier said Wednesday in a statement that also included second-quarter financial results. The airline was among those that pulled annual outlooks in April, after uncertainty stoked by President Donald Trump's tariff policies rattled business and consumer confidence and cratered demand early in the year. Increased business travel — particularly in the tech industry — that started late in the second quarter has persisted this month as companies see more stability in the macroeconomy, Chief Financial Officer Shane Tackett said. 'That's been a good development,' Tackett said in an interview. 'We're optimistic that if it remains, we could have a stronger second half than the first as some demand that stepped down comes back.' The recent pickup in travel is particularly important for Alaska as it continues combining operations with Hawaiian, which it acquired in September. Alaska and other US-focused carriers were more affected by the early drop in demand than rivals including United Airlines Group Inc. and Delta Air Lines Inc. that also have extensive international operations. Alaska will limit flying capacity growth in the second half of the year. The carrier expects third quarter seating to be 1% lower than 2024 on demand that's below its expectations during off-peak travel times. Smaller airlines are broadly expected to slow growth after the summer travel period in an effort to better match demand and boost fares. The airline also said it expects a third-quarter adjusted earnings per share of $1 to $1.40. That is lower than the $1.65 average of analyst estimates compiled by Bloomberg. Wall Street was expecting a 2025 adjusted profit of $3.31 per share. Alaska has taken delivery of two Embraer SA E175 aircraft that it delayed earlier this year on the threat of possible tariffs, Tackett said. The airline is set to receive three more next year and will have to evaluate 'whether or not those assets make economic sense for us' if tariffs force Embraer to increase prices markedly. Embraer's chief executive officer has said punitive tariffs threatened by Trump could add $9 million to the price of each plane. Alaska's adjusted second-quarter profit was $1.78 a share, topping the $1.53 average from analyst estimates. Revenue was $3.7 billion, while analysts were expecting $3.66 billion. More stories like this are available on
Mint
3 hours ago
- Mint
PDD Analysts See HK Listing as More Likely After Auditor Change
(Bloomberg) -- PDD Holdings Inc.'s move to switch to a Hong Kong-based auditor may indicate the Chinese e-commerce firm is preparing to apply for a second listing there, according to two analysts. The parent company of budget shopping app Temu said in a filing on Wednesday that it has tapped Hong Kong-based auditors of Ernst & Young for a review of its financial statements this year. The firm previously worked with Beijing-based Ernst & Young Hua Ming LLP. Such a shift likely suggests that PDD is pursuing a listing in Hong Kong over coming months, according to Citigroup analyst Alicia Yap. 'If this proves to be true, we believe this could be viewed as a positive catalyst for the share price,' she said. PDD did not immediately reply to an emailed request for comment outside of office hours. PDD's American depositary receipts rose as much as 5.6% to the highest in two months. The firm is among the relatively few US-listed Chinese names that have yet to list in Hong Kong, a group that also includes retailer Vipshop Holdings Ltd. and tutoring firm TAL Education Group. Companies like Alibaba Group Holding Ltd., Inc. and Baidu Inc. have already secured a second listing in Hong Kong amid persistent concerns that they could get booted off American exchanges. In April, US Treasury Secretary Scott Bessent said all options are 'on the table' when asked about potential delistings of Chinese companies. A second listing would potentially enable investors of Chinese firms to convert ADRs to Hong Kong shares in the event of a US delisting. Upgrading the Hong Kong listing to a primary status — like what Alibaba did last year — will also allow mainland buyers to tap into the stock. Felix Wang, an analyst at Hedgeye Risk Management, noted that companies preparing to list in Hong Kong often engage with local auditors to comply with regulatory requirements. That was the case for both Alibaba and when they sought Hong Kong listings, he said. 'One of the frustrations on PDD in the past is the company not interested in issuing a secondary IPO' to expand its investor base, Wang said in a note. 'Is PDD changing its mind on listing in HK? It can only help with investor sentiment.' More stories like this are available on
Mint
7 hours ago
- Mint
Dr. Reddy's US generics business drags Q1 earnings, eyes weight-loss drug launch in 87 countries
Dr Reddy's Laboratories Ltd's US generics business slumped in the June quarter as it faced price erosion in key products like gRevlimid used to treat cancer. US generics revenue declined 11% year-on-year and 4% sequentially to ₹ 3,412 crore in the first quarter of FY26, according to earnings announced on Wednesday. The business accounts for 40%, the highest among all segments, of its top line. The base business remains stable despite the price erosion, the company's management said in a post-earnings press conference. 'This time, as we knew, we are in the last year of lenalidomide or Revlimid [exclusivity], so this actually was very predictable,' said chief executive officer Erez Israeli. He added that the timing of procurement of key products, as well as the lack of new launches during the quarter, added to the drag in US earnings. The company posted an overall revenue from operations of ₹ 8,545 crore in Q1, up 11% over a year earlier. Its profit after tax rose 2% year-on-year to ₹ 1,418 crore. Both the metrics missed estimates. A Bloomberg poll had pegged its revenue to be ₹ 8,690 crore and profit after tax at ₹ 1,513 crore. The company posted an Ebitda of ₹ 2,278 crore, up 5% on-year, with its margins contracting to 26.7% in Q1 from 28.2% a year earlier. Ebitda is earnings before interest, tax, depreciation and amortization, a measure of operational profitability. The company's revenues in other key markets recorded healthy growth. Its Europe business grew 142% on-year to ₹ 1,274 crore, driven by its nicotine replacement therapy (NRT) portfolio acquired from Haleon last year. The India business grew 11% on-year to ₹ 1,471 crore on the back of new product launches and price increases. The company plans to launch weight-loss drug semaglutide in 87 countries next year, including those where patents are expiring and emerging markets where there are no patents, Israeli said. The drug goes off patent in several countries starting 2026. Semaglutide is a GLP-1 (Glucagon-like peptide-1), a class of medications indicated for the treatment of type-2 diabetes and obesity. 'We have some countries where there is no patent. And in others, we need to wait for the patent expiration…We are absolutely planning to launch day one in each one of these markets,' Israeli said. 'The biggest markets that will be ready for a launch will be Canada, India, Brazil, and Turkey.' The drugmaker is currently embroiled in a patent dispute with innovator Novo Nordisk in India. Semaglutide goes off patent in India in March 2026. Dr Reddy's has completed submissions of relevant regulatory filings in each of the countries where it plans to launch and is 'expecting approvals prior to the launch date', said Israeli. The company expects sales of semaglutide and other GLP-1s to be huge growth drivers. 'The sales of the product itself is big and can come to hundreds of millions of dollars…it depends on the price and market share we are getting [but] the beauty of this product is that we believe that once the price will go down, significantly more patients will use this product for both type-2 diabetes as well as weight loss,' he said. 'We believe this is a group (GLP-1s) with a lot of potential, and again, the sizes can be hundreds of millions of dollars; and therefore significant in the growth of the company in the next year,' he added. Through the next decade, the company plans to roll out 26 GLP-1 products including semaglutide, tirzepatide and others as they go off patent. Dr Reddy's shares closed 0.65% higher at ₹ 1,248.00 on Wednesday on NSE, compared with a 0.63% rise in Nifty 50, before the company announced its results.
